TY - JOUR
T1 - Reintervention risk and quality of life outcomes after uterine-sparing interventions for fibroids
T2 - a systematic review and meta-analysis
AU - Sandberg, Evelien M.
AU - Tummers, Fokkedien H.M.P.
AU - Cohen, Sarah L.
AU - Van Den Haak, Lukas
AU - Dekkers, Olaf M.
AU - Jansen, Frank Willem
PY - 2018
Y1 - 2018
N2 - Objectives: To compare uterine-sparing treatment options for fibroids in terms of reintervention risk and quality of life. Design: Systematic review and meta-analysis according to PRISMA guidelines. Setting: Not applicable. Patient(s): Women with uterine fibroids undergoing a uterine-sparing intervention. Interventions(s): Not applicable. Main Outcome Measure(s): 1) Reintervention risk after uterine-sparing treatment for fibroids after 12, 36, and 60 months; and 2) quality of life outcomes, based on validated questionnaires. Two separate analyses were performed for the procedures that used an abdominal approach (myomectomy, uterine artery embolization [UAE], artery ligation, high-intensity focused ultrasound [HIFU], laparoscopic radiofrequency ablation [RFA]) and for the procedures managing intracavitary fibroids (hysteroscopic approach, including hysteroscopic myomectomy and hysteroscopic RFA). Result(s): There were 85 articles included for analysis, representing 17,789 women. Stratified by treatment options, reintervention risk after 60 months was 12.2% (95% confidence interval [CI] 5.2%–21.2%) for myomectomy, 14.4% (95% CI 9.8%–19.6%) for UAE, 53.9% (95% CI 47.2%–60.4%) for HIFU, and 7% (95% CI 4.8%–9.5%) for hysteroscopy. For the other treatment options, no studies were available at 60 months. For quality of life outcomes, symptoms improved after treatment for all options. The HIFU procedure had the least favorable outcomes. Conclusion(s): Despite the substantial heterogeneity of the study population, this meta-analysis provides valuable information on relative treatment efficacy of various uterine-sparing interventions for fibroids, which is relevant when counseling patients in daily practice. Furthermore, this study demonstrates that long-term data, particularly for the newest uterine-sparing interventions, are urgently needed.
AB - Objectives: To compare uterine-sparing treatment options for fibroids in terms of reintervention risk and quality of life. Design: Systematic review and meta-analysis according to PRISMA guidelines. Setting: Not applicable. Patient(s): Women with uterine fibroids undergoing a uterine-sparing intervention. Interventions(s): Not applicable. Main Outcome Measure(s): 1) Reintervention risk after uterine-sparing treatment for fibroids after 12, 36, and 60 months; and 2) quality of life outcomes, based on validated questionnaires. Two separate analyses were performed for the procedures that used an abdominal approach (myomectomy, uterine artery embolization [UAE], artery ligation, high-intensity focused ultrasound [HIFU], laparoscopic radiofrequency ablation [RFA]) and for the procedures managing intracavitary fibroids (hysteroscopic approach, including hysteroscopic myomectomy and hysteroscopic RFA). Result(s): There were 85 articles included for analysis, representing 17,789 women. Stratified by treatment options, reintervention risk after 60 months was 12.2% (95% confidence interval [CI] 5.2%–21.2%) for myomectomy, 14.4% (95% CI 9.8%–19.6%) for UAE, 53.9% (95% CI 47.2%–60.4%) for HIFU, and 7% (95% CI 4.8%–9.5%) for hysteroscopy. For the other treatment options, no studies were available at 60 months. For quality of life outcomes, symptoms improved after treatment for all options. The HIFU procedure had the least favorable outcomes. Conclusion(s): Despite the substantial heterogeneity of the study population, this meta-analysis provides valuable information on relative treatment efficacy of various uterine-sparing interventions for fibroids, which is relevant when counseling patients in daily practice. Furthermore, this study demonstrates that long-term data, particularly for the newest uterine-sparing interventions, are urgently needed.
KW - quality of life
KW - Reintervention risk
KW - uterine-sparing treatment option
UR - http://www.scopus.com/inward/record.url?scp=85045049604&partnerID=8YFLogxK
U2 - 10.1016/j.fertnstert.2017.11.033
DO - 10.1016/j.fertnstert.2017.11.033
M3 - Article
AN - SCOPUS:85045049604
VL - 109
SP - 698
EP - 707
JO - Fertility and Sterility
JF - Fertility and Sterility
SN - 0015-0282
IS - 4
ER -